Biocardia stock.

BioCardia Inc ( BCDA) is lower by Wednesday morning, with the stock declining -4.67% in pre-market trading to 1.02. BCDA's short-term technical score of 100 indicates that the stock has traded more bullishly over the last month than 100% of stocks on the market. In the Biotechnology industry, which ranks 123 out of 146 industries, the stock ...BioCardia, Inc. reports earnings inline with expectations. Reported EPS is $-0.12 EPS, expectations were $-0.12. Operator: Ladies and gentlemen, thank you for standing by and welcome to the ...BioCardia Inc (BCDA) stock is trading at $2.16 as of 10:19 AM on Friday, Jun 9, an increase of $0.04, or 1.89% from the previous closing price of $2.12. The stock has traded between $2.15 and $2.18 so far today. Volume today is light. So far 5,707 shares have traded compared to average volume of 41,498 shares.BioCardia ( NASDAQ: BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical trial of its CardiAMP autologous cell therapy for the ...SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics …

6 hari yang lalu ... BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of ...Nov 30, 2023 · BioCardia, Inc. (NASDAQ:BCDA) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.05. The business had revenue of $0.82 million for the quarter, compared to analysts' expectations of $0.04 million. Sep 5, 2023 · The treated group median 6MWT at 12M increased 36.1 with a standard deviation of ±70.8 meters, and the control group median 6MWT increased at 12M by 33.4 meters ± 74.8 meters (p =0.6). Results ...

Oct 11, 2023 · Over the past 3 months, 4 analysts have published their opinion on BioCardia (NASDAQ:BCDA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a ... Nov 7, 2023 · BCDA Stock Shows Promising Performance with Potential 863.86% Increase: Analysts Recommend Buying BioCardia Inc. BCDA stock has shown promising performance on November 7, 2023, according to data sourced from CNN Money. The median target price is $4.00, indicating a potential increase of 863.86% from the last recorded price of $0.42.

SUNNYVALE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...16 Nov 2023 ... BioCardia develops cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. Stock BCDA logo. BioCardia ...Simon Stertzer owns over 166,666 units of BioCardia stock worth over $1,450,986 and over the last 7 years he sold BCDA stock worth over $0. In addition, he makes $76,250 as Independent Chairman of the Board at BioCardia. Wallmine is a radically better financial terminal. Sign up in seconds, it's free!The estimated Net Worth of Simon H Stertzer is at least $1.55 Миллион dollars as of 5 July 2019. Simon Stertzer owns over 166,666 units of BioCardia stock worth over $1,476,667 and over the last 6 years he sold BCDA stock worth over $0. In addition, he makes $76,250 as Independent Chairman of the Board at BioCardia.

Nov 14, 2023 · BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 14d Why Beyond Air Shares Are Trading Lower By Around 37%?

The estimated Net Worth of Richard M Krasno is at least $410 millier dollars as of 17 June 2019. Mr. Krasno owns over 20,000 units of BioCardia stock worth over $140,000 and over the last 16 years he sold BCDA stock worth over $0. In addition, he makes $269,814 as Independent Director at BioCardia.

FORM OF. SECURITIES PURCHASE AGREEMENT. This Securities Purchase Agreement (this "Agreement") is dated as of November 16, 2023, between BioCardia, Inc., a Delaware corporation (the "Company"), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a "Purchaser" …Biocardia trades on the NASDAQ stock market under the symbol BCDA. What is Biocardia stock price doing today? As of November 29, 2023, BCDA stock price declined to $0.68 with 702,007 million shares trading.Joseph Pantginis, an analyst from H.C. Wainwright, has initiated a new Buy rating on BioCardia ().. Joseph Pantginis’ Buy rating for BioCardia’s stock (BCDA) is based on a combination of ...8 Nov 2023 ... Stock name: BCDA, Stock Code: BCDA, Company: BioCardia, Inc., Sector: Healthcare.Exhibit 4.1 [Director Deferred Settlement—Fixed Date] BIOCARDIA, INC. 2016 EQUITY INCENTIVE PLAN. RESTRICTED STOCK UNIT AGREEMENT . Unless otherwise defined herein, the terms defined in the BioCardia, Inc. 2016 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement (the “Award …Full Company Report for BCDA. View BioCardia, Inc BCDA investment & stock information. Get the latest BioCardia, Inc BCDA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ...Nov 17, 2023 · Source. Headline. Genocea Biosciences (NASDAQ:GNCAQ) vs. BioCardia (NASDAQ:BCDA) Financial Analysis. americanbankingnews.com - November 17 at 1:30 AM. BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. finance.yahoo.com - November 16 at 3:00 PM. 6 hari yang lalu ... BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of ...Nov 24, 2023 · BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmo... Shares of BioCardia Inc. sank 13.9% in morning trading Wednesday, after the developer of regenerative biologic therapies announced more stock sales in the wake of the 137.6% rocket ride over... Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.SAN CARLOS, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for ...

Biocardia Stock Ownership FAQ. Who owns Biocardia? Biocardia ( NASDAQ: BCDA) is owned by 7.68% institutional shareholders, 908.30% Biocardia 0.00% retail investors. Phillip Md Et Al Frost is the largest individual Biocardia shareholder, owning 151.76M shares representing 701.96% of the company. Phillip Md Et Al Frost's Biocardia shares …

Nov 14, 2023 · SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ... BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmo...A. BioCardia ( BCDA) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2023 for Q3 and the Actual Revenue was $357K, which beat ...Ladies and gentlemen, thank you for standing by, and welcome to the BioCardia 2023 third-quarter conference call. (Operator Instructions) Participants of this call are advised that the audio of this conference call is being broadcasted live over the Internet and is also being recorded for playback purposes. A webcast replay of this call will be ...Analysts who follow BioCardia Inc on average expect it to increase 1150.00% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns BioCardia Inc an Analyst Ranking of 25, which means it ranks higher than 25 of stocks, based on data compiled by InvestorsObserver.Nov 26, 2023 · Website. n/a. 33. Peter Altman. https://www.biocardia.com. BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of ... BioCardia (BCDA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright remains neutral on the stock and ...On November 15, 2023, BioCardia achieved a major breakthrough as it obtained FDA authorization for its groundbreaking CardiAMP Heart Failure ... BCDA stock has shown promising performances on November 15, 2023, with positive price forecasts and a consensus among analysts to buy the stock. However, investors should conduct further …2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval 16 Nov 2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

Discover historical prices for BCDA stock on Yahoo Finance. View daily, weekly or monthly format back to when BioCardia, Inc. stock was issued.

Mr. McClung BCDA stock SEC Form 4 insiders trading. David has made over 5 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,600 units of BCDA stock worth $4,096 on 5 November 2018.1,600 units of BCDA stock worth $4,096 on 5 November 2018.

Find the latest BioCardia, Inc. (6JU.F) stock quote, history, news and other vital information to help you with your stock trading and investing.BioCardia stock rises on FDA nod to start trial of stem cell therapy for heart failure Dec. 06, 2022 8:33 AM ET BioCardia, Inc. (BCDA) By: Ravikash , SA News Editor 1 Comment Sarah SilbigerThe estimated Net Worth of Richard M Krasno is at least $385 Thousand dollars as of 17 June 2019. Mr. Krasno owns over 20,000 units of BioCardia stock worth over $114,800 and over the last 17 years he sold BCDA stock worth over $0. In addition, he makes $269,814 as Independent Director at BioCardia.Discover historical prices for BCDA stock on Yahoo Finance. View daily, weekly or monthly format back to when BioCardia, Inc. stock was issued. Description. BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular and pulmonary diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus on heart failure ...Nov 20, 2023 · The stock of BioCardia Inc. (BCDA) has seen a 84.85% increase in the past week, with a 84.37% gain in the past month, and a -16.66% decrease in the past quarter. The volatility ratio for the week is 30.21%, and the volatility levels for the past 30 days are at 12.77% for BCDA. The simple […] Nov 8, 2023 · BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 0% and 614%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive ... BCDA | Complete BioCardia Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.The estimated Net Worth of Peter Altman is at least $875 mil dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $197,402 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer y Director at BioCardia.5 Sep 2023 ... Biocardia stock dropped from about $2 on July 21 to $1.10 on July 24, when the concerns of the DSMB were first revealed. After drifting down ...

A high-level overview of BioCardia, Inc. (BCDA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Get the latest BioCardia (BCDAW) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. ... Stock Market ...You can buy and sell BioCardia (BCDA) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. Other Robinhood Financial fees may apply, check rbnhd.co/fees for details. ... BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular ...Instagram:https://instagram. outer patio furnitureday trading cash accountvanguard total bond indexmedical marijuanas stock price BCDAW | Complete BioCardia Inc. Wt stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. online motorcycle insurance quote state farmveng stock prices The estimated Net Worth of Peter Altman is at least $747 Mille dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $69,056 and over the last 6 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer e Director at BioCardia.BioCardia announces that the Food and Drug Administration (FDA) has approved its proposed CardiAMP Heart Failure II study protocol. The currently ongoing CardiAMP Heart Failure trial has completed enrollment and it is anticipated that the final data analyses will be reported in fourth quarter 2024. how much is a 1000 gram gold bar worth The estimated Net Worth of Peter Altman is at least $913 Thousand dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $235,166 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer, and Director at BioCardia.SAN CARLOS, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for ...